The next generation of diabetic nephropathy therapies: An update

Advances in Chronic Kidney Disease

Volumn 12, Issue 2, 2005, Pages 212-222

  Williams, Mark E ^a   Tuttle, Katherine R ^b  

^a JOSLIN DIABETES CENTER   (United States)

^b NONE

Author keywords

Advanced glycation end product inhibition; Diabetic nephropathy; Novel therapies; Protein kinase C inhibition; Sulodexide, pyridoxamine

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; ANTIDIABETIC AGENT; DANAPAROID; DERMATAN SULFATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTEIN KINASE C BETA; PROTEIN KINASE C INHIBITOR; PYRIDORIN; PYRIDOXAMINE; RUBOXISTAURIN; SULODEXIDE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DIABETIC NEPHROPATHY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MICROALBUMINURIA; NEUROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

EID: 16844376137     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2005.01.011     Document Type: Article

References (89)

1. M.L. Caramori, M. Mauer Diabetes and nephropathy Curr Opin Nephrol Hypertens 12 2003 273 282
2. F. Locatelli, B. Canaud, K.U. Eckardt The importance of diabetic nephropathy in current nephrological practice Nephrol Dial Transplant 8 2003 716 725
3. P. Muntner, J. Coresh, N.R. Power The contribution of increased diabetes prevalence and improved myocardial infarction and stroke survival to the increase in treated end-stage renal disease J Am Soc Nephrol 14 2003 1568 1577
4. United States Renal Data System Annual Data Report 2001 Incidence and prevalence of ESRD Am J Kidney Dis 38 suppl 2001 S37 S52
5. United States Renal Data System Annual Data Report 2003 Incidence and prevalence of ESRD Am J Kidney Dis 42 suppl 2003 S47 S60
6. U.S. Renal Data System USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. 2004 National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD
7. A. Gordois, P. Scuffham, A. Shearer The health care costs of diabetic nephropathy in the United States and the United Kingdom J Diabetes Complications 18 2004 18 26
8. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 329 1993 977 986
9. UK Prospective Diabetes Study (UKPDS) Group Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
10. M. Shichiri, H. Kishikawa, Y. Ohkubo Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients Diabetes Care 23 2000 B21 B29
11. H.H. Parving, U.M. Smidt, E. Hommel Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy Am J Kidney Dis 22 1993 188 195
12. E.J. Lewis, L.G. Hunsicker, R.P. Bain The effect of angiotensin- converting-enzyme inhibition on diabetic nephropathy N Engl J Med 329 1993 1456 1462
13. B.M. Brenner, M.E. Cooper, D. de Zeeuw Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 2001 861 869
14. E.J. Lewis, L.G. Hunsicker, W.R. Clarke Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 2001 851 860
15. M.T. Pedrini, A.S. Levey, J. Lau The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases A meta-analysis Ann Intern Med 124 1996 627 632
16. B.L. Kasiske, J.D.A. Lakatua, J.Z. Ma A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function Am J Kidney Dis 31 1998 954 961
17. H.P. Hansen, E. Tauber-Lassen, B.R. Jensen Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy Kidney Int 62 2002 220 228
18. P. Gaede, P. Vedel, N. Larsen Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 2003 383 393
19. C. Dai, J. Yang, S. Bastacky Intravenous administration of heypatocyte growth factor gene ameliorates diabetic nephropathy in mice J Am Soc Nephrol 15 2004 2637 2647
20. B.I. Hudson, L.G. Bucciarelli, T. Wendt Blockade of receptor for advanced glycation end products A new target for therapeutic intervention in diabetic complications and inflammatory disorders Arch Biochem Biophys 419 2003 80 88
21. M.P. Cohen, E. Hud, V.-Y. Wu Amelioration of diabetic nephropathy by treatment with monoclonal antibodies against glycated albumin Kidney Int 45 1994 1673 1679
22. M.P. Cohen Intervention strategies to prevent pathogenetic effects of glycated albumin Arch Biochem Biophys 419 2003 25 30
23. D.J. Kelly, Y. Zhang, R. Gow Tranilast attenuates structural and functional aspects of renal injury in the remnant kidney model J Am Soc Nephrol 15 2004 2619 2629
24. W.K. Bolton, D.C. Cattran, M.E. Williams Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy Am J Nephrol 24 2004 32 40
25. G. Gambaro, I. Kinalska, A. Oksa Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: The Di.N.A.S. randomized trial J Am Soc Nephrol 13 2002 1615 1625
26. F.A. Ofosu Pharmacological actions of sulodexide Semin Thromb Hemost 24 1998 127 138
27. M. Ceol, G. Gambaro, U. Sauer Glycosaminoglycan therapy prevents TGF-B1 overexpression and pathologic changes in renal tissue of long-term diabetic rats J Am Soc Nephrol 11 2000 2324 2336
28. G. Gambaro, A.P. Venturini, D.M. Noonan Treatment with glycosaminoglycan formulation ameliorates experimental diabetic nephropathy Kidney Int 46 1994 797 806
29. G. Gambaro, A.O. Cavazzana, P. Luzi Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats Kidney Int 42 1992 285 291
30. H.B. Nader, V. Buonassisi, P. Colburn Heparin stimulates the synthesis and modifies the sulfation pattern of heparan sulfate proteoglycan from endothelial cells J Cell Physiol 140 1989 305 310
31. C. Caenazzo, S. Garbisa, M. Ceol Heparin modulates proliferation and proteoglycan biosynthesis in murine mesangial cells Molecular clues for its activity in nephropathy Nephrol Dial Transplant 20 1995 175 184
32. G. Gambaro, B. Baggio Glycosaminoglycans A new paradigm in the prevention of proteinuria and progression of glomerular disease Nephrol Dial Transplant 11 1996 762 764
33. A. Solini, L. Vergnani, F. Ricci Glycosaminoglycans delay the progression of nephropathy in NIDDM Diabetes Care 20 1997 819 823
34. M. Velussi, A.M. Cernigoi, F. Dapas Glycosaminoglycans oral therapy reduces macroalbuminuria, blood fibrinogen levels and limb arteriopathy clinical signs in patients with non-insulin dependent diabetes mellitus Diabetes Nutr Metab 9 1996 53 58
35. A. Poplawska, M. Szelachowska, B. Topolska Effect of glycosaminoglycans on urinary albumin excretion in insulin-dependent diabetic patients with micro- or macroalbuminuria Diabetes Res Clin Pract 38 1997 109 114
36. D.S.C. Raj, D. Choudhury, T.C. Welbourne Advanced glycation end-products A nephrologist's perspective Am J Kidney Dis 35 2000 365 380
37. A. Heidland, K. Sebekova, R. Schinzel Advanced glycation end products and the progressive course of renal disease Am J Kidney Dis 38 suppl 1 2001 S100 S106
38. J.M. Forbes, M.E. Cooper, M.D. Oldfield Role of advanced glycation end products in diabetic nephropathy J Am Soc Nephrol 14 suppl 2003 S54 S58
39. M.E. Williams New therapies for advanced glycation end product nephrotoxicity Current challenges Am J Kidney Dis 41 suppl 1 2003 S42 S47
40. M. Brownlee Biochemistry and molecular cell biology of diabetic complications Nature 414 2001 813 820
41. F.F. Hou, H. Ren, W.F. Owen Enhanced expression of receptor for advanced glycation end products in chronic kidney disease J Am Soc Nephrol 15 2004 1889 1896
42. C. Lu, J.C. He, W. Cai Advanced glycation end product (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells Proc Natl Acad Sci USA 101 2004 11767 11772
43. G. Jerums, S. Panagiotopoulos, J. Forbes Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease Arch Biochem Biophysics 419 2003 55 62
44. M. Sabbatini, G. Sansone, F. Uccello Early glycosylation products induce glomerular hyperfiltration in normal rats Kidney Int 42 1992 875 881
45. M. Bendayan Immunocytochemical detectin of advanced glycated end products in rat renal tissue as a function of age and diabetes Kidney Int 54 1998 438 447
46. S. Youssef, D.T. Nguyen, T. Soulis Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding Kidney Int 55 1999 907 916
47. E. Abdel-Rahman, W.K. Bolton Pimagedine A novel therapy for diabetic nephropathy Expert Opin Investig Drugs 11 2002 565 574
48. M.E. Williams Clinical studies of advanced glycation end-product inhibitors and diabetic kidney disease Curr Diabetes Rep 4 2004 441 446
49. M. Kalousova, T. Zima, V. Vesai Advanced glycation end products in clinical nephrology Kidney Blood Press Res 27 2004 18 28
50. D. Edelstein, M. Brownlee Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine Diabetes 41 1992 26 29
51. T.O. Metz, N.L. Alderson, S.R. Thorpe Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions A novel therapy for treatment of diabetic complications Arch Biochem Biophys 419 2003 41 49
52. N.L. Alderson, M.E. Chachich, N.Y. Youssef The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats Kidney Int 63 2003 2123 2133
53. T.P. Degenhardt, N.L. Alderson, D.D. Arrington Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat Kidney Int 61 2000 939 950
54. A. Stitt, T.A. Gardiner, N.L. Anderson The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes Diabetes 51 2002 2826 2832
55. M.E. Williams, W.K. Bolton, T.P. Degenhardt A phase 2 clinical trial of pyridoxamine (Pyridorin) in type 2 and type 2 diabetic patients with overt nephropathy (PYR-206) J Am Soc Nephrol 14 2003 7A
56. H. Schaumburg, J. Kaplan, A. Windebakn Sensory neuropathy from pyridoxine abuse A new megavitamin syndrome N Engl J Med 309 1983 445 448
57. T. Miiyata, C. Van Ypersele de Strihou, Y. Euda Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products Biochemical mechanisms J Am Soc Nephrol 13 2002 2478 2487
58. J.B. McGill, M.E. Williams, T.P. Degenhardt A phase 2 clinical investigation of pyridoxamine (Pyridorine) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR 205-207) J Am Soc Nephrol 15 2004 565A
59. S. Vasan, P. Foiles, H. Founds Therapeutic potential of breakers of advanced glycation end product-protein crosslinks Arch Biochem Biophys 419 2003 89 96
60. S. Rahbar, J.L. Figarola Novel inhibitors of advanced glycation end products Arch Biochem Biophys 419 2003 63 79
61. A.J. Bailey, R.G. Paul, L. Knott Mechanisms of maturation of ageing of collagen Mech Ageing Dev 106 1998 1 56
62. R. Singh, A. Barden, T. Mori Advanced glycation end-products A review Diabetologia 44 2001 129 146
63. M.S.P. Huijberts, B.H.R. Wolffenbuttel, H. Boudier Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats J Clin Invest 92 1993 1407 1411
64. M. Brownlee, H. Vlassara, A. Kooney Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking Science 232 1986 1629 1632
65. S. Vasan, X. Zhang, X. Zhang An agent cleaving glucose-derived protein crosslinks in vitro and in vivo Nature 382 1996 275 278
66. V. Tallas-Bonke, C. Lindschau, B. Rizkalla Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711, a protein kinase C-alpha-dependent pathway Diabetes 53 2004 2921 2930
67. D. Susic, J. Varagic, J. Ahn Cardiovascular and renal effects of a collagen cross-link breaker (ALT-711) in adult and aged spontaneously hypertensive rats AJH 17 2004 328 333
68. D.A. Kass, E.P. Shapiro, M. Kawaguchi Improved arterial compliance by a novel advanced glycation end-product crosslink breaker Circulation 104 2001 1464 1470
69. D. Susic, J. Varagic, J. Ahn Crosslink breakers A new approach to cardiovascular therapy Curr Opin Cardiol 19 2004 336 340
70. K.R. Tuttle, P.W. Anderson A novel potential therapy for diabetic nephropathy and vascular complications Protein kinase C beta inhibition Am J Kidney Dis 42 2003 456 465
71. P.A. Craven, F.R. DeRubertis Protein kinase C is activated in glomeruli from streptozotocin diabetic rats Possible mediation by glucose J Clin Invest 83 1989 1667 1675
72. S.H. Ayo, R. Radnik, J.A. Garoni High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell cultures Am J Physiol 261 1991 F571 F577
73. F.R. DeRubertis, P.A. Craven Activation of protein kinase C in glomerular cells in diabetes Mechanisms and potential links to the pathogenesis of diabetic glomerulopathy Diabetes 43 1994 1 8
74. T. Inoguchi, T. Sonta, H. Tsubouchi Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes Role of vascular NAD(P)H oxidase J Am Soc Nephrol 14 suppl 2003 S227 S232
75. K.R. Tuttle, E.C. Johnson, S.K. Cooney Amino acids injure mesangial cells by advanced glycation end products, oxidative stress, and protein kinase C Kidney Int 67 2005 953 968
76. T. Inoguchi, R. Battan, E. Handler Preferential elevation of protein kinase C isoform βII and diacylglycerol levels in the aorta and heart of diabetic rats Differential reversibility to glycemic control by islet cell transplantation Proc Natl Acad Sci USA 89 1992 11059 11063
77. T. Shiba, T. Inoguchi, J.R. Sportsman Correlation of diacylglycerol level and protein kinase C activity in rat retinal circulation Am J Physiol 265 1993 E783 E793
78. H. Ishii, M.R. Jirousek, D. Koya Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor Science 272 1996 728 731
79. M.R. Jirousek, J.R. Gillig, C.M. Gonzalez (S)-13-[(dimethylamino)methyl]- 10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H,13H-dibenzo[e,k]pyrrolo[3,4-h][1, 4,13]-oxadiazacyclohexadecene-1,3(2H)-dione(ruboxistaurin) and related analogues Isozyme selective inhibitors of protein kinase Cβ J Med Chem 39 1996 2664 2671
80. D. Koya, M.R. Jirousek, Y.-W. Lin Characterization of protein kinase C β isoform activation on the gene expression of transforming growth factor-β, extracellular matrix components and prostanoids in the glomeruli of diabetic rats J Clin Invest 100 1997 115 126
81. D. Koya, M. Haneda, H. Nakagawa Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes FASEB J 14 2000 439 447
82. D.J. Kelly, Y. Zhang, C. Hepper PKC β inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension Diabetes 52 2003 512 518
83. V. Scivittaro, M.B. Ganz, M.F. Weiss AGEs induce oxidative stress and activate protein kinase C-bII in neonatal mesangial cells Am J Physiol Renal Physiol 278 2000 F676 F683
84. C.I. Whiteside, J.A. Dlugosz Mesangial cell protein kinase C isozyme activation in the diabetic milieu Am J Physiol Renal Physiol 282 2002 F975 F980
85. M. Kitada, D. Koya, T. Sugimoto Translocation of glomerular p47phox and p67phox by protein kinase C-β activation is required for oxidative stress in diabetic nephropathy Diabetes 52 2003 2603 2614
86. M. Malhotra, B.P.S. Kang, S. Cheung Angiotensin II promotes glucose-induced activation of cardiac protein kinase C isozymes and phosphorylation of troponin I Diabetes 50 2001 1918 1926
87. T.M. Osiicka, Y. Yu, V. Lee Aminoguanidine and ramipril prevent diabetes-induced increases in protein kinase C activity in glomeruli, retina, and mesenteric artery Clin Sci 100 2001 249 257
88. American Diabetes Association Standards of medical care for patients with diabetes mellitus Diabetes Care 25 2002 213 229
89. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Pharmacological therapy diabetic kidney disease Am J Kidney Dis 43 suppl 2004 S142 S158